Aytu BioPharma, Inc.AYTUNASDAQ
Loading
Year-over-year research & development expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P54
Within normal range
Streak
1 qtr
Consecutive growthDecelerating
Average
68.86%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | -100.00% |
| Q2 2025 | 33.33% |
| Q1 2025 | -68.97% |
| Q4 2024 | 22.54% |
| Q3 2024 | -59.20% |
| Q2 2024 | 70.87% |
| Q1 2024 | 17.27% |
| Q4 2023 | -12.44% |
| Q3 2023 | 27.96% |
| Q2 2023 | -45.68% |
| Q1 2023 | -49.94% |
| Q4 2022 | 60.71% |
| Q3 2022 | -67.29% |
| Q2 2022 | -0.88% |
| Q1 2022 | -26.66% |
| Q4 2021 | 170.88% |
| Q3 2021 | -65.32% |
| Q2 2021 | 1121.54% |
| Q1 2021 | 36.36% |
| Q4 2020 | 56.28% |
| Q3 2020 | -87.79% |
| Q2 2020 | 1809.25% |
| Q1 2020 | 17.74% |
| Q4 2019 | -14.54% |
| Q3 2019 | -55.48% |
| Q2 2019 | 60.94% |
| Q1 2019 | -26.93% |
| Q4 2018 | -4.39% |
| Q3 2018 | -17.95% |
| Q2 2018 | 66.45% |
| Q1 2018 | 141.13% |
| Q4 2017 | -296.86% |
| Q3 2017 | -23.94% |
| Q2 2017 | -67.54% |
| Q1 2017 | 83.34% |
| Q4 2016 | 11.23% |
| Q3 2016 | -90.24% |
| Q2 2016 | 140.65% |
| Q1 2016 | -12.15% |